Colorectal Cancer

The addition of ramucirumab to second-line FOLFIRI resulted in a delay in disease progression and improved survival in metastatic colorectal cancer patients.

Newly diagnosed metastatic colorectal cancer patients with higher vitamin D levels had better outcomes after treatment with chemotherapy and a targeted agent.

Rectal cancer patients who completed neoadjuvant therapy with a clinical complete response had similar 4-year survival rates as patients who opted for surgery.

Initial treatment with FOLFOXIRI plus bevacizumab in metastatic colorectal cancer patients improved survival over FOLFIRI and bevacizumab by more than 4 months.

The results of a recent meta-analysis suggest that carriers of the MLH1 or MSH2 mutations associated with Lynch syndrome could delay regular colonoscopies until age 30.

Researchers are estimating that about 3.6% of new cancer cases in 2012 in adults may be attributed to a high BMI, equating to about 481,000 new cancer cases.

A significant proportion of deaths due to colorectal cancer in southern states, and half of deaths due to colorectal cancer nationwide are a result of racial/ethnic, socioeconomic, and geographic disparities.

Researchers have identified a mechanism that could explain how NSAIDs lower the risk of developing intestinal polyps that can transform into colon cancer.

Developing a scoring system for staging patients with hepatic colorectal metastases is important for prognosis and for identifying those who will benefit from additional systemic therapy.

Due to advances in chemotherapy, biologic therapy, and the development of liver-oriented treatment options, the survival of patients with metastatic cancer has more than doubled, and increasing numbers of patients have been cured, even among those with advanced disease.

This article will review the current practice of hepatic resection for colorectal liver metastases, including the possibility of combined resection of hepatic metastases at the time of resection of the primary cancer.

People who underwent genetic and environmental risk assessment evaluating their colorectal cancer risk were no more likely to undergo screening for the disease.

Only 14% of newly diagnosed lung or colorectal cancer patients reported discussing clinical trial participation with their physician, and fewer participated.

Adopting a combination of five healthy behaviors is linked to a reduction in the risk of developing colorectal cancer, according to the results of a study.

The management of rectal cancer in patients with metastatic disease at presentation is highly variable. Although chemoradiation is standard for patients with stage II/III rectal cancer, its role in the metastatic setting is controversial.

The management of colorectal cancer is a complex endeavor that requires treatment individualization founded on molecular characterization of the tumor, an in-depth understanding of the patient, and an appreciation of the interaction between the two.

A 35-year study of males in Sweden found a link between obesity and inflammation during adolescence and a risk for colorectal cancer in adulthood.

Two French studies have shown that screening for colorectal cancer with fecal occult blood tests can be very effective, according to results presented at the ESMO 2014 Congress.

Adding cetuximab (Erbitux) to the standard first-line FOLFIRI chemotherapy regimen results in longer overall survival in metastatic colorectal cancer patients.

A systematic, best-practice approach to colorectal surgery can decrease the risk of surgical site infections, according to a new study.

This article discusses features that predict local recurrence and distant metastasis in rectal cancer, and how to use MRI to guide treatment decisions.

There are a number of clinicopathologic variables that predict outcome in rectal cancer. In the era of postoperative chemoradiation treatment, these were more easily identified and were used to help select patients for adjuvant therapy.

The authors propose that current policies regarding the use of chemoradiotherapy or short-course preoperative radiotherapy have resulted in an approach to rectal cancer management that often represents overtreatment, with significant loss of quality of life for patients.

Yesterday, the US Food and Drug Administration (FDA) approved the first DNA-based stool sample screening test for colorectal cancer.

A comprehensive analysis of studies and trials suggests the cancer prevention benefits of a daily aspirin for at least 5 years outweigh the potential harms.